List of works - Sebastian J C M M Neggers

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

scientific article

Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors ⬇️

scientific article published on December 14, 2012

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

scientific article

Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma ⬇️

scientific article published on April 16, 2012

Bridging the gap: metabolic and endocrine care of patients during transition

scientific article

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

scientific article published on 6 May 2015

Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

scientific article published on 17 July 2015

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study

scientific article published on 4 August 2010

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

scientific article

Combination treatment with somatostatin analogues and pegvisomant in acromegaly

scientific article

Combined treatment of somatostatin analogues with pegvisomant in acromegaly

scientific article

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients ⬇️

scientific article published on September 1, 2011

Des-acyl ghrelin: a metabolically active peptide

scientific article published on 25 April 2013

Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage

scientific article published on 14 September 2013

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

scientific article published on 15 November 2017

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

scientific article published on 12 October 2018

Emotional distress in 652 Dutch very long-term survivors of childhood cancer, using the hospital anxiety and depression scale (HADS).

scientific article published in October 2013

Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia

scientific article published on 9 January 2013

Extra-hepatic Acromegaly

scientific article published on 15 March 2013

Gonadal function recovery in very long-term male survivors of childhood cancer ⬇️

scientific article published on January 5, 2013

How to Position Pasireotide LAR Treatment in Acromegaly

scientific article published on 01 June 2019

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

scientific article published on 13 March 2017

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

scientific article published on 15 April 2014

Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: evidence from accelerometer-based activity monitoring

scientific article published on 23 November 2017

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

scientific article

Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer ⬇️

scientific article published on February 14, 2013

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

scientific article published on 22 May 2017

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

scientific article published on 17 June 2014

Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin

scientific article published on 16 August 2012

Medical approach to pituitary tumors

scientific article published on January 2014

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues

scientific article

Modulation of Glucocorticoid Metabolism by the GH-IGF-I Axis ⬇️

scientific article published on December 16, 2010

Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer ⬇️

scientific article published on August 14, 2012

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

scientific article published on 01 March 2019

Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors

scientific article published on February 1, 2013

Pegvisomant Treatment in Acromegaly

scientific article

Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly

scientific article published on 01 April 2020

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.

scientific article published on 4 August 2015

Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions

scientific article published on 13 March 2018

Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study

scientific article published on 6 November 2014

Pregnancy and acromegaly.

scientific article

Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review

scientific article published on 28 July 2009

Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration W

scientific article

Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the [...]

scientific article

Review of current and emerging treatment options in acromegaly

scientific article

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

scientific article

Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?

scientific article published on 07 April 2014

Soluble Klotho: a possible predictor of quality of life in acromegaly patients

scientific article published on 24 April 2020

Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects

scientific article

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

scientific article published on 25 July 2016

Somatostatin analog and pegvisomant combination therapy for acromegaly

scientific article published on October 2009

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

scientific article

T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

scientific article published on 01 June 2020

T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

scientific article published on 20 September 2016

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.

scientific article

The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens

scientific article published on 11 April 2017

The limited screening value of insulin‐like growth factor‐i as a marker for alterations in body composition in very long‐term adult survivors of childhood cancer ⬇️

scientific article published on December 11, 2011

The metabolic syndrome in adult survivors of childhood cancer, a review

scientific article published on April 2010

The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study

scientific article published on 24 April 2020

Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors

scientific article published in October 2012

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states

scientific article

Very long-term sequelae of craniopharyngioma.

scientific article

What is active acromegaly and which parameters do we have? ⬇️

scientific article published on May 1, 2012

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

scientific article published on 22 February 2016

X-linked acrogigantism syndrome: clinical profile and therapeutic responses

scientific article

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.

scientific article published on 29 October 2013

List of works by Sebastian J C M M Neggers

A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues.

Abdominal Radiotherapy: A Major Determinant of Metabolic Syndrome in Nephroblastoma and Neuroblastoma Survivors ⬇️

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.

Adrenal function in adult long-term survivors of nephroblastoma and neuroblastoma ⬇️

Bridging the gap: metabolic and endocrine care of patients during transition

Changes in circulating IGF1 receptor stimulating activity do not parallel changes in total IGF1 during GH treatment of GH-deficient adults

Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients.

Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

Combination treatment with somatostatin analogues and pegvisomant in acromegaly

Combined treatment of somatostatin analogues with pegvisomant in acromegaly

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients ⬇️

Des-acyl ghrelin: a metabolically active peptide

Diagnostic value of a ghrelin test for the diagnosis of GH deficiency after subarachnoid hemorrhage

Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).

Efficacy and Safety of switching to Pasireotide in Acromegaly Patients controlled with Pegvisomant and Somatostatin Analogues: PAPE extension study

Emotional distress in 652 Dutch very long-term survivors of childhood cancer, using the hospital anxiety and depression scale (HADS).

Endocrine sequelae and metabolic syndrome in adult long-term survivors of childhood acute myeloid leukemia

Extra-hepatic Acromegaly

Gonadal function recovery in very long-term male survivors of childhood cancer ⬇️

How to Position Pasireotide LAR Treatment in Acromegaly

In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.

In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life

Inactive lifestyles and sedentary behavior in persons with chronic aneurysmal subarachnoid hemorrhage: evidence from accelerometer-based activity monitoring

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study

Long-Term Nephrotoxicity in Adult Survivors of Childhood Cancer ⬇️

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly

Mechanisms in endocrinology: Ghrelin: the differences between acyl- and des-acyl ghrelin

Medical approach to pituitary tumors

Medical therapy of acromegaly: efficacy and safety of somatostatin analogues

Modulation of Glucocorticoid Metabolism by the GH-IGF-I Axis ⬇️

Obesity Is Underestimated Using Body Mass Index and Waist-Hip Ratio in Long-Term Adult Survivors of Childhood Cancer ⬇️

Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors

Pegvisomant Treatment in Acromegaly

Pegvisomant and not somatostatin receptor ligands (SRLs) is first line medical therapy for acromegaly

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.

Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions

Pituitary dysfunction after aneurysmal subarachnoid haemorrhage: course and clinical predictors—the HIPS study

Pregnancy and acromegaly.

Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review

Recommendations for Premature Ovarian Insufficiency Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer: A Report From the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration W

Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the [...]

Review of current and emerging treatment options in acromegaly

Risk factors for subsequent endocrine-related cancer in childhood cancer survivors

Should we consider des-acyl ghrelin as a separate hormone and if so, what does it do?

Soluble Klotho: a possible predictor of quality of life in acromegaly patients

Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.

Somatostatin analog and pegvisomant combination therapy for acromegaly

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study

T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis.

The acylated/unacylated ghrelin ratio is similar in acromegaly patients during different treatment regimens

The limited screening value of insulin‐like growth factor‐i as a marker for alterations in body composition in very long‐term adult survivors of childhood cancer ⬇️

The metabolic syndrome in adult survivors of childhood cancer, a review

The role of AIP variants in pituitary adenomas and concomitant thyroid carcinomas in the Netherlands: a nationwide pathology registry (PALGA) study

Treatment factors rather than genetic variation determine metabolic syndrome in childhood cancer survivors

Unacylated ghrelin modulates circulating angiogenic cell number in insulin-resistant states

Very long-term sequelae of craniopharyngioma.

What is active acromegaly and which parameters do we have? ⬇️

What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?

X-linked acrogigantism syndrome: clinical profile and therapeutic responses

β-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly.